©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
G13 Stimulates Na-H Exchange through Distinct Cdc42-dependent and RhoA-dependent Pathways (*)

(Received for publication, October 19, 1995; and in revised form, January 4, 1996)

Rebecca Hooley Chun-Yuan Yu Marc Symons (1) Diane L. Barber (§)

From the Departments of Stomatology and Surgery, University of California, San Francisco, California 94143 and Onyx Pharmaceutics, Richmond, California 94306

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Activity of the ubiquitously expressed Na-H exchanger subtype NHE1 is stimulated upon activation of receptor tyrosine kinases and G protein-coupled receptors. The intracellular signaling pathways mediating receptor regulation of the exchanger, however, are poorly understood. Using transient expression of dominant interfering and constitutively active alleles in CCL39 fibroblasts, we determined that the GTPases Ha-Ras and Galpha13 stimulate NHE1 through distinct signaling cascades. Exchange activity stimulated by constitutively active RasV12 occurs through a Raf1- and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase kinase (MEK)-dependent mechanism. Constitutively active Galpha13QL, recently shown to stimulate the Jun kinase cascade, activates NHE1 through a Cdc42- and MEK kinase (MEKK1)-dependent mechanism that is independent of Rac1. Constitutively active Rac1V12 does stimulate NHE1 through a MEKK1-dependent mechanism, but dominant interfering Rac1N17 does not inhibit Galpha13QL-mediated or constitutively active Cdc42V12-mediated stimulation of the exchanger. Conversely, Cdc42N17 does not inhibit Rac1V12 activation of NHE1, suggesting that Rac1 and Cdc42 independently regulate a MEKK1-dependent activation of the exchanger. Rapid (<10 min) stimulation of NHE1 with a Galpha13/Galpha(z) chimera also was inhibited by a kinase-inactive MEKK. Galpha13QL, but not RasV12, also stimulates NHE1 through a RhoA-dependent pathway that is independent of MEKK, and microinjection of mutationally active Galpha13 results in a Rho phenotype of increased stress fiber formation. These findings indicate a new target for Rho-like proteins: the regulation of H exchange and intracellular pH. Our findings also suggest that a MEKK cascade diverges to regulate effectors other than transcription factors.


INTRODUCTION

The ubiquitously expressed Na-H exchanger subtype NHE1 (^1)plays a major role in intracellular pH (pH) homeostasis and in cell volume regulation(1) . NHE1 activity is stimulated by hormones, cytokines, and growth factors, resulting in an increase in pH. Hyperosmotic shock (2) and cell adhesion (3) also activate NHE1. Increases in NHE1 activity are associated with increased cell proliferation(4, 5) , differentiation(6, 7) , and neoplastic transformation(8, 9, 10) . Receptor (11, 12) , but not osmotic(2) , activation of NHE1 is associated with increased phosphorylation of the exchanger on serine residues, suggesting kinase-dependent regulatory mechanisms. Although activation of protein kinase C stimulates NHE1, growth factors and vasoactive agents can stimulate the exchanger independently of this kinase. Mutational activation of three GTPases, Ha-Ras(8, 9) , Galpha(q)(13, 14, 15) , and Galpha13(13, 14, 15) , stimulates NHE1 activity. Of these GTPases, only Galpha(q) activates the exchanger through a protein kinase C-dependent mechanism (14) . (^2)The downstream signaling events mediating Ha-Ras and Galpha13 stimulation of NHE1 have not been identified. Ha-Ras and Galpha13 regulate two parallel MAP kinase signaling cascades, and these cascades include serine/threonine protein kinases that could potentially modulate exchange activity.

Stimulation of one of these cascades, the extracellular signal-regulated kinase (ERK) cascade, by activated growth factor receptor tyrosine kinases is mediated by the GTPase Ras. GTP-bound Ras recruits an immediate downstream effector, Raf1, to the plasma membrane, where it is activated by an unidentified mechanism(16, 17) . The serine/threonine kinase Raf1 activates the MAP kinase kinases MEK1 and MEK2(18) . These dual-specificity kinases phosphorylate and activate the MAP kinases ERK1 and ERK2(19) . Activated ERKs regulate a wide range of cytosolic and nuclear proteins involved in cell proliferation and neoplastic transformation, including phospholipase A(2), p90, c-Myc, and c-Fos(19, 20) . Heterotrimeric G proteins, both alpha (21, 22, 23) and beta(23, 24, 25) subunits, also regulate the ERK cascade, although their action on ERK is more cell type-specific than that of Ras. For example, mutational activation of the ubiquitously expressed Galpha13 subunit stimulates growth and neoplastic transformation in Rat1 (22) and NIH3T3(26, 27) fibroblasts; however, it enhances epidermal growth factor-stimulated ERK activity in the former cell type(22) , but does not affect this kinase in the latter(26, 27) . In already transformed COS-7 cells, mutationally activated Galpha13 has been found both to inhibit (^3)and to have no effect (24, 28) on ERK activity. In contrast to its cell-specific effects on the ERK cascade, Galpha13 consistently stimulates NHE1 activity in a wide range of cell types, suggesting a divergence in its actions on ERK and the exchanger.

Recently, a parallel MAP kinase cascade, the Jun kinase (JNK) or stress-activated protein kinase cascade, has been described(18, 29, 30) . Identified substrates of JNK/stress-activated protein kinase are the transcription factors c-Jun and AFT2(31) . The JNK cascade is activated by epidermal growth factor (32) and UV irradiation (33) through a Ras-dependent mechanism and by cytokines in a Ras-independent manner(30, 34) . Recently, Galpha13 was found to activate the JNK cascade through a mechanism that is interrupted by the dominant interfering allele RasN17(28) . Extracellular signals activating JNK are mediated through activation of MEK kinase (MEKK1), a mammalian homolog of the STE11 kinase involved in the yeast pheromone mating pathway(35) . MEKK1 directly activates the stress-activated protein-kinase kinase SEK1 (JNK kinase), a direct upstream regulator of JNK(36, 37) . Upstream, although probably not direct regulators of MEKK1, are two members of the Rho subfamily of GTPases, Rac1 and Cdc42 (38, 39) . These GTPases are also involved in the organization of the actin cytoskeleton. Rac1 regulates membrane ruffling and lamellipodia (40, 41) , and Cdc42 controls the formation of filopodia(41, 42) . Although morphological studies suggest that Cdc42 acts upstream of Rac1 and Rac2(41, 42) , their sequential regulation of JNK remains unclear. Coexpression of a dominant negative Rac1N17 with constitutively activated Cdc42V12 does not inhibit(38) , or only partially inhibits (39) , JNK activation, indicating that these GTPases may independently regulate the JNK cascade.

Ha-Ras and Galpha13 are highly oncogenic, and their regulation of the ERK and JNK cascades may be critical for their transforming actions. The ability of these GTPases to constitutively stimulate NHE1 activity and the correlation of increased exchange activity with transformed phenotypes indicate the importance of determining the mechanisms mediating GTPase regulation of NHE1. In this study, we used dominant interfering alleles of kinases and GTPases to determine the mechanisms by which Ha-Ras and Galpha13 activate NHE1. Although Ha-Ras and Galpha13 regulate both the ERK and JNK cascades, our results indicate that Ha-Ras stimulates the exchanger through a Raf1- and MEK1-dependent mechanism that is independent of MEKK1. In contrast, Galpha13 activates NHE1 through a MEKK1-dependent mechanism that requires Cdc42, but not Rac1. Galpha13, but not Ras, also stimulates exchange activity through a Rho-dependent mechanism that is independent of MEKK1.


MATERIALS AND METHODS

Cell Culture and Transfections

Chinese hamster lung CCL39 fibroblasts were cultured in Dulbecco's modified Eagle's medium supplemented with 5% heat-inactivated fetal bovine serum. 18 h prior to transfections, cells were plated at a density of 0.8 times 10 in 60-mm dishes. Cells were transfected using the Lipofectamine method (Life Technologies, Inc.) with 1-3 µg of DNA. pcDNA empty vector was used to maintain total transfected DNA constant. 18 h after transfection, cells were reseeded in serum-containing Dulbecco's modified Eagle's medium onto glass coverslips, allowed to adhere, and then maintained for an additional 18-24 h in serum-free Dulbecco's modified Eagle's medium until used for measuring NHE1 activity.

Expression Plasmids

Ha-RasV12, Galpha13QL, Galpha13/alpha(z), and D(2)-dopamine receptor subcloned into pcDNAI were obtained from T. Voyno-Yasenetskaya and H. Bourne and were previously described(13, 22) . v-Raf, Naf, and wild-type Raf were provided by A. MacNichol and subcloned into pcDNA3 (Invitrogen) at EcoRI/XbaI sites. These Raf1 constructs have a 5`-untranslated sequence from the human Raf1 gene and a KT3 epitope tag at their 3`-ends(43) . MEK and MEKK constructs were provided by G. Johnson(32, 35) . The kinase-inactive form of mouse MEK, referred to as MEK-Km (K343M point mutation), was subcloned into pcDNA3 at BamHI/EcoRV sites with a BamHI-blunted HindIII fragment. Wild-type MEKK1 and its kinase-inactive form, MEKK1-Km (K432A point mutation), were subcloned into pcDNA3 at EcoRI/XhoI sites. The constitutively activated MEKK1Delta allele contains an N terminus truncation (amino acids 1-352), but retains an intact catalytic domain (amino acids 353-674). The MEKK1Delta construct was made by placing a NcoI-SspI fragment into a SmaI site of pCMV. Both MEKKDelta and MEKK1-Km were C-terminally tagged with a HA epitope. pEXV-MycRac1V12 and pEXV-MycRac1N17 were previously described (44) , as were pEXV-MycRhoAV14 and pEXV-MycRhoAN19 (referred to in this paper as RhoAV14 and RhoAN19, respectively)(45) . pCMV-MycCdc42V12 and pCMV-MycCdc42N17 were gifts of M. Hart and A. Abo. pEXV-PA encoding protein A was provided by J. Hancock.

NHE Activity

For pH(i) determinations, cells were transferred to a nominally HCO(3)-free HEPES-buffered medium (46) and loaded with a 1 µM concentration of the acetoxymethyl ester derivative of the pH-sensitive dye 2`,7`-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (Molecular Probes, Inc.) for 15 min at 37 °C. 2`,7`-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein fluorescence was measured using a Shimadzu RF5000 spectrofluorometer by alternately exciting the dye at 500 and 440 nm at a constant emission of 530 nm. Fluorescence ratios were calibrated with 10 µM nigericin in 105 mM KCl(47) . Cells were acid-loaded by the application (10 min) and removal of 20 mM NH(4)Cl (48) . Rates of recovery from this acid load (dpH(i)/dt) were determined by evaluating the derivative of the slope of the pH(i) tracing at pH(i) intervals of 0.05. Data represent the mean ± S.E. of the indicated number of separate cell transfections.

Immunoblotting

Immunoblot analyses were made from cells prepared for pH(i) determinations to ensure that samples used for Western blots and pH(i) determinations had similar levels of protein expression. After the glass coverslips were removed for fluorescence measurements, cell lysates were prepared from the remaining adherent cells. Samples were normalized for protein content, and 25 µg of protein was resolved by SDS-polyacrylamide gel electrophoresis. Resolved proteins were transferred to nylon-supported nitrocellulose (Alameda Chemicals & Science, Inc.). After nonspecific binding sites were blocked, the filters were incubated with an anti-Myc antibody at a 1:1000 dilution. Immunopositive proteins were detected by chemiluminescence (Amersham Corp.).

Microinjection and Immunofluorescence

CCL39 cells were microinjected with plasmids in the nucleus, incubated in serum-free Dulbecco's modified Eagle's medium for 5 h, and fixed in 4% formaldehyde in Ca/Mg-free phosphate-buffered saline. Immunofluorescence procedures using anti-Myc antibodies to visualize injected cells were carried out essentially as described previously(16) . Cells were also stained with fluorescein isothiocyanate-labeled phalloidin (Sigma) at 0.5 µg/ml.


RESULTS

Ras and Galpha13 Use Distinct Kinase Cascades to Stimulate NHE1

Both Ras and Galpha13 regulate ERK and JNK. To determine whether the kinase cascades leading to ERK and JNK activation mediate stimulation of NHE1, we transiently expressed constitutively active kinases and GTPases and dominant negative kinases in CCL39 fibroblasts. NHE1 activity was determined by monitoring the rate of pH(i) recovery from an acute acid load induced by 20 mM NH(4)Cl. We first studied the role of Raf1, an immediate downstream effector of Ras(49) . Expression of constitutively active v-Raf, RasV12, and alpha13QL stimulated NHE1 activity (Fig. 1A). The resting pH(i) of 6.97 ± 0.02 (mean ± S.E.) in vector controls also increased, to 7.18 ± 0.02 with v-Raf, to 7.11 ± 0.02 with RasV12, and to 7.12 ± 0.01 with alpha13QL (n = four separate transfections). We then cotransfected a kinase-deficient Raf1 (Naf) allele with these GTPases. This dominant interfering kinase specifically blocks activation of endogenous Raf1 activity(43) . Naf completely inhibited RasV12-activated exchange activity (Fig. 1A) and decreased RasV12-induced resting pH(i) to 6.97 ± 0.03 (n = 4). Coexpression of wild-type Raf1 at a 1:1 ratio with Naf rescued the Naf-inhibited activation by RasV12 (Fig. 1A). Naf, however, had no effect on alpha13QL-stimulated exchange activity (Fig. 1A) or on alpha13QL-induced resting pH(i) (7.11 ± 0.03 in the presence of Naf; n = 4). In three separate transfections, coexpression of Naf also failed to inhibit activation of NHE1 by mutationally active Galpha(q)RC (data not shown). These findings suggested that Ras, but not Galpha13 or Galpha(q), stimulates NHE1 through a Raf1-dependent mechanism.


Figure 1: Distinct kinases mediate RasV12 and alpha13QL stimulation of NHE1. The rate of pH recovery (dpH/dt times 10 pH/s) from an acute acid load was determined in CCL39 cells transiently expressing empty vector (pcDNA) or the indicated kinases and GTPases. Data are expressed as the recovery rate at pH 6.75. A, Raf1 regulation of NHE1 activity was determined by measuring recovery rates in cells expressing pcDNA or constitutively active v-Raf, RasV12, and alpha13QL alone (control) or coexpressed with a dominant interfering Raf1 (+ Naf). Recovery rates also were determined in cells coexpressing RasV12, Naf, and wild-type Raf (+ Naf + wtRaf). B, MEK-regulated NHE1 activity was determined in cells expressing pcDNA, RasV12, and alpha13QL in the absence (control) or presence (+ MEK-Km) of a dominant interfering MEK. C, the role of MEKK1 in stimulating NHE1 was determined in cells expressing pcDNA or constitutively active MEKK1Delta, RasV12, and alpha13QL alone (control) or coexpressed with a dominant interfering MEKK1 (+ MEKK-Km). Data represent the mean ± S.E. of recovery rates in four to five separate transfections.



Although Raf1 may act on several substrates, the MAP kinase kinase proteins MEK1 and MEK2 are its preferred targets(18) . We used a catalytically inactive MEK-Km allele (35) to investigate MEK-dependent activation of NHE1. Coexpression of MEK-Km completely inhibited RasV12 activation of NHE1 (Fig. 1B) and lowered RasV12-induced resting pH(i) from 7.13 ± 0.02 to 6.97 ± 0.03 (n = 4). Ras therefore activates NHE1 by the same pathway as it activates ERK. MEK-Km, however, had no effect on alpha13QL-induced NHE1 activity (Fig. 1B) or on resting pH(i) (data not shown).

Ras (29, 30) and Galpha13 (28) also activate the JNK cascade, which suggests that another signaling pathway may mediate the effect of these GTPases on NHE1. The lack of suitable dominant interfering or constitutively active alleles of JNK and its upstream regulator JNK kinase limited our study to the role of MEKK1, an upstream regulator of JNK(36, 37) , in stimulating the exchanger. Expression of a constitutively active carboxyl-terminal truncated MEKK1 (MEKK1Delta) increased NHE1 activity (Fig. 1C) and increased the resting pH(i) from 7.00 ± 0.02 in vector controls to 7.16 ± 0.04 (n = 3). Coexpression of a kinase-inactive MEKK1-Km with RasV12 had no effect on Ras-stimulated exchange activity (Fig. 1C) or on Ras-induced increases in pH(i) (7.12 ± 0.02 in the absence and 7.11 ± 0.01 in the presence of MEKK1-Km; n = 4). Coexpression of MEKK1-Km with alpha13QL, however, completely inhibited G13-stimulated exchange activity (Fig. 1C) and reduced the G13-induced resting pH(i) from 7.12 ± 0.02 to 7.00 ± 0.03 (n = 5). Galpha13, but not Ras, therefore uses a MEKK1-dependent pathway to stimulate NHE1.

Members of the Rho Family of GTPases Couple to the Activation of NHE1

Recently, two members of the Rho subfamily of GTPases, Rac1 and Cdc42, were determined to activate the JNK cascade(38, 39) . A third member of this family, Rho, does not couple to this signaling pathway(39, 50) . To examine whether these GTPases can regulate NHE1 activity, we transiently expressed the constitutively active alleles Rac1V12, Cdc42V12, and RhoAV14 in CCL39 fibroblasts. In three separate transfections, expression of each constitutively active GTPase resulted in an increase in exchange activity (Fig. 2). Additionally, the resting pH(i) of 6.98 ± 0.01 in vector controls increased to 7.14 ± 0.02 with Rac1V12, to 7.18 ± 0.04 with Cdc42V12, and to 7.09 ± 0.02 with RhoAV14. Coexpression of MEK-Km had no effect on Rac1V12 or Cdc42V12 stimulation of NHE1 (Fig. 2). Coexpression of MEKK1-Km with these alleles, however, completely inhibited their activation of the exchanger (Fig. 2) and reduced resting pH(i) to 7.01 ± 0.02 with Rac1V12 and to 7.02 ± 0.03 with Cdc42V12. In contrast, MEKK1-Km failed to reduce increases in either NHE1 activity (Fig. 2) or resting pH(i) induced by RhoAV14, confirming the specificity of its inhibitory effects on Rac1V12 and Cdc42V12. Hence, the mechanism whereby these small G proteins activate the exchanger is different, as Rac1 and Cdc42, but not RhoA, act through a MEKK1-dependent pathway. The MEKK1-independent effects of both Ras and Rho on NHE1 suggested that a Rho-mediated pathway may be an additional mechanism linking Ras to the exchanger. In three separate transfections, however, coexpression of a dominant interfering RhoAN19 had no effect on Ras-induced increases in exchange activity or resting pH(i) (data not shown).


Figure 2: Rho family proteins stimulate NHE1 activity. Rates of pH recovery from an acid load were determined at pH 6.75 in CCL39 cells transiently expressing pcDNA or constitutively active Rac1V12, Cdc42V12, and RhoAV14 alone (control) or coexpressed with either dominant interfering MEK1 (+ MEK-Km) or dominant interfering MEKK1 (+ MEKK-Km). Data represent the mean ± S.E. of recovery rates in three separate transfections.



Cdc42 and RhoA, but Not Rac1, Mediate Galpha13 Activation of NHE1

Because all three members of the Rho family stimulated NHE1 activity, we examined their role in mediating Galpha13 actions. Expression of a dominant interfering Rac1N17 had no effect on the actions of alpha13QL on exchange activity (Fig. 3A) or on resting pH(i) (7.12 ± 0.01 in the absence and 7.13 ± 0.02 in the presence of Rac1N17; n = 6). Dominant interfering Cdc42N17 (Fig. 3B) and RhoAN19 (Fig. 3C), however, completely blocked NHE1 stimulation by alpha13QL. The resting pH(i) also decreased, from 7.12 ± 0.01 with alpha13QL alone to 6.97 ± 0.02 (n = 4) with coexpression of Cdc42N17 and to 6.96 ± 0.03 (n = 4) with coexpression of RhoAN19. The inhibitory actions of Cdc42N17 and RhoAN19 were specific, as neither dominant interfering allele blocked RasV12 activation of the exchanger (data not shown). Rac1N17 was expressed at levels comparable to Cdc42N17 (Fig. 3D), suggesting that its inability to block alpha13QL activation of NHE1 was not attributed to the lack of protein expression. Rac1N17 also failed to inhibit NHE1 activity stimulated by RasV12 (data not shown). Although we found no condition that could serve as a positive control to confirm the dominant interfering function of Rac1N17, this plasmid construct was previously used to block the transforming action of RasV12(44) . Hence, the inhibition of alpha13QL-stimulated NHE1 activity by Cdc42N17, but not by Rac1N17, suggests that Rac1 may not act downstream of Cdc42, as was previously suggested by morphological studies(41, 42) . Recent reports on Cdc42 and Rac1 activation of JNK also failed to establish a clear hierarchal action of these Rho-related GTPases(38, 39) . To further confirm the independent actions of the Rho family of GTPases on NHE1, we examined the ability of their dominant interfering alleles to inhibit stimulation by their constitutively active alleles. Rac1N17 had no effect on Cdc42V12; Cdc42N17 had no effect on Rac1V12 or RhoAV14 stimulation; and RhoAN19 had no effect on Cdc42V12 stimulation (Fig. 4).


Figure 3: alpha13QL stimulation of NHE1 activity is inhibited by Cdc42N17 and RhoAN19, but not Rac1N17. The rates of pH recovery at the indicated pH values were determined in CCL39 cells transiently expressing empty vector (pcDNA) or alpha13QL or coexpressing alpha13QL and the indicated dominant interfering Rho family proteins. Data represent the mean ± S.E. of recovery rates in four to six separate transfections. A, coexpression of Rac1N17 had no effect on alpha13QL stimulation of NHE1 activity. B, coexpression of Cdc42N17 blocked alpha13QL-stimulated exchange. C, coexpression of RhoAN19 also blocked alpha13QL-stimulated exchange. D, expression of Myc-tagged Rac1N17 and Cdc42N17 was determined by immunoblotting with an anti-Myc antibody.




Figure 4: Rho family proteins have independent effects on NHE1 activity. Rates of pH recovery at pH6.75 were determined in CCL39 cells transiently expressing pcDNA or the indicated constitutively active Rho family proteins in the absence or presence of the indicated dominant interfering Rho family proteins. Data represent the mean ± S.E. of recovery rates in three separate transfections.



Members of the Rho family have distinct effects on the actin cytoskeleton. Rac1 regulates membrane ruffling and lamellipodia(40, 41) ; Cdc42 controls the formation of filopodia(41, 42) ; and RhoA induces stress fiber formation(40) . We next examined the effect of alpha13QL on the actin cytoskeleton by plasmid microinjection followed by immunofluorescence microscopy. CCL39 cells expressing alpha13QL were contracted and showed a marked increase in stress fiber formation (Fig. 5, A and B), which was very similar to the phenotype induced by expression of RhoAV14 (Fig. 5, C and D). In contrast, expression of Rac1V12 caused cell spreading and stimulated lamellipodia formation (Fig. 5, E and F), whereas Cdc42V12-expressing cells showed enhanced formation of filopodia and, to a much lesser extent, of lamellipodia as well (Fig. 5, G and H). These results suggest that of the Rho family members, RhoA may be the primary target of Galpha13 activation.


Figure 5: Expression of alpha13QL causes enhanced stress fiber formation. Shown are fluorescence micrographs of CCL39 cells expressing alpha13QL (A and B), RhoAV14 (C and D), Rac1V12 (E and F), and Cdc42V12 (G and H). A, C, E, and G, fluorescein isothiocyanate-labeled phalloidin staining; B, protein A staining visualized by indirect immunofluorescence using anti-Myc antibody to mark injected cells; D, F, and H, Myc staining visualizing expression of the respective epitope-tagged GTPases. Rac1-induced lamellipodia are indicated by thick arrows in F. Cdc42-induced filopodia are indicated by thin arrows in H. Bar = 10 µm.



Acute Activation of NHE1 by a Galpha13/alpha(z) Chimera Is Mediated by MEKK1

We have primarily studied NHE1 stimulation by the mutationally activated alpha13QL, which allows us to determine effects ascribed to a single GTPase. The effects of alpha13QL, however, could reflect an indirect response because this constitutively active Galpha subunit was expressed for 48 h before NHE1 activity was measured. To study rapid effects of Galpha13, we used an alpha13/alpha(z) chimeric protein that allows specific receptor-mediated activation of Galpha13. This chimera was constructed by substituting the five carboxyl-terminal residues of alpha13, which are thought to specify receptor recognition, with cognate residues of Galpha(z)(13) . Because the D(2)-dopamine receptor (D(2)R) activates Galpha(z), but not Galpha13, we previously used this chimeric allele in HEK293 cells to demonstrate rapid stimulation of NHE1 by activation of the D(2)R(13) . In CCL39 cells, activation of an alpha13/alpha(z) chimera also resulted in a rapid stimulation of the exchanger (Fig. 6). Quinpirole, a D(2)R agonist, had no effect on NHE1 activity in cells expressing empty vector (pcDNA) or the D(2)R. In cells coexpressing the D(2)R and the alpha13/alpha(z) chimera, however, quinpirole stimulated exchange activity (Fig. 6A), inducing a rapid increase in the rate of pH(i) recovery from an acid load (Fig. 6B). Stimulation of NHE1 by quinpirole activation of alpha13/alpha(z) was completely inhibited by MEKK1-Km, whereas MEK-Km had no effect (Fig. 6C). These findings indicate that rapid as well as constitutive activation of NHE1 by Galpha13 can be mediated by MEKK1. This mechanism of acute stimulation of the exchanger suggests that nuclear transcription factors, the previously described targets of a MEKK1-dependent signaling cascade, are probably not involved in a Galpha13-MEKK1-NHE1 pathway. Coupling to NHE1 may therefore represent a divergence in MEKK1 signaling.


Figure 6: Acute activation of NHE1 by an alpha13/alpha(z) chimera is inhibited by dominant interfering MEKK-Km. A, rates of pH recovery from an acid load were determined at pH 6.75 in CCL39 cells transiently expressing pcDNA or the D(2)R or coexpressing the D(2)R and alpha13/alpha(z) chimeric protein. Recovery rates were determined in the absence (box) or presence () of the D(2)R agonist quinpirole (100 nM). B, shown is the time course of pH recovery from an NH(4)Cl prepulse in CCL39 cells expressing the D(2)R and alpha13/alpha(z). Recoveries were determined in HEPES buffer in the absence (left trace) and presence (right trace) of quinpirole. C, acute activation of NHE1 by alpha13/alpha(z) was inhibited by coexpression of MEKK-Km, but not MEK-Km.




DISCUSSION

The ubiquitously expressed Na-H exchanger NHE1 is one of several ion exchangers involved in cytoplasmic pH homeostasis. Activation of NHE1 increases the rate of H efflux from the cell, resulting in a rise in pH(i). Although the kinetics of NHE1 activation by growth factors, hormones, and cytokines has been extensively studied(1) , post-receptor signaling mechanisms regulating the exchanger remain largely unknown. This study focuses on the signaling pathways mediating activation of NHE1 by Ha-Ras and Galpha13. Although these GTPases regulate similar kinase cascades, our findings indicate they use distinct mechanisms to stimulate NHE1 activity (Fig. 7). It is not surprising that Raf1 and MEK, which act downstream of Ras, mediate RasV12 activation of the exchanger. ERK, a selective substrate for MEK(19) , is also a likely component in Ras activation of NHE1, although there is currently no direct evidence for an ERK-dependent regulation of the exchanger. Galpha13 also regulates ERK(22) ; however, it stimulated NHE1 activity independently of the Ras/Raf pathway. It is unknown how Galpha13 regulates ERK; if the Galpha13 signal acts directly on ERK, then the dominant interfering alleles of Raf1 and MEK used in this study would not block an ERK-mediated activation of NHE1.


Figure 7: Distinct signaling pathways mediate Ha-Ras and Galpha13 stimulation of NHE1 activity. Ha-Ras stimulation of NHE1 occurs through activation of Raf1 and MEK, but independently of the Rho family of GTPases and MEKK. Although the Rho family of GTPases (Rac1, Cdc42, and RhoA) stimulate NHE1, their upstream regulation and coupling to the exchanger are distinct. Rac1 and Cdc42 activate NHE1 through a MEKK1-dependent mechanism, whereas RhoA couples to the exchanger independently of MEKK1. Galpha13 activation of NHE1 is mediated by Cdc42 and RhoA, but not by Rac1. The downstream signaling pathways used by MEK, MEKK1, and Rho to stimulate NHE1 are undetermined.



Our findings identify NHE1 as a previously undescribed effector of a MEKK1 signaling pathway. A role for MEKK1 in activating the exchanger was determined by several experiments. First, a constitutively activated amino-terminal truncated MEKK1 increased NHE1 activity and pH(i). Second, a kinase-inactive MEKK1-Km inhibited NHE1 activation by constitutively activated Rac1V12, Cdc42V12, and alpha13QL. This inhibition was specific, as MEKK1-Km had no effect on NHE1 activity stimulated by RasV12 or RhoAV14. Third, acute stimulation of the exchanger by D(2)R activation of an alpha13/alpha(z) chimeric protein was also inhibited by MEKK1-Km. This latter finding argues against a role for transcriptional regulation in a Galpha13-MEKK1-NHE1 pathway, suggesting a divergence in the actions of MEKK1 on nuclear factors and NHE1, an integral plasma membrane protein. JNK, a downstream effector of MEKK(37) , is stimulated by Ras through a Rac-dependent mechanism(38, 39) . Ras activation of NHE1, however, occurs independently of Rac and MEKK1. A likely explanation for this is that perhaps a critical threshold of MEKK1 activation must be attained to signal downstream to the exchanger. Ras stimulates only a modest increase in JNK activity (29, 38, 39) that is much less potent than its activation of ERK. Additionally, we consistently find that JNK activation by alpha13QL is 3-4 times greater than that by RasV12. (^4)The distinct mechanisms whereby Ras and Galpha13 stimulate NHE1 are not consistent with recent findings that Galpha13 stimulates JNK through a Ras-dependent mechanism(28) . A Ras-mediated activation of JNK by Galpha13, however, could function in regulating effectors other than NHE1.

Our findings also identify NHE1 as a previously undescribed downstream effector of the Rho family of GTPases. Although three members of this family, Rac1, Cdc42, and RhoA, stimulated NHE1 activity, their upstream regulation and their coupling to the exchanger were distinct. Rac1 and Cdc42, recently shown to stimulate JNK activity(38, 39, 52) , activated NHE1 through a MEKK1-dependent mechanism, whereas RhoA coupled to the exchanger independently of MEKK1. Galpha13 activation of NHE1 was mediated by Cdc42 and Rho, but not by Rac, indicating that Galpha13 does not regulate Rac. Dbl, a tissue-specific proto-oncogene, functions as a guanine nucleotide exchange factor for Cdc42 and RhoA, but not Rac1(53) . Although speculative, our findings suggest that perhaps a Dbl homolog expressed in CCL39 cells may act downstream of Galpha13. If Cdc42- and Rho-mediated pathways are divergently regulated by Galpha13, it is uncertain why a dominant interfering allele of either monomeric GTPase completely blocked alpha13QL activation of NHE1. One possibility is that Galpha13 activation of the exchanger requires a cooperative action of Cdc42 and RhoA. Another explanation is that Cdc42N17 or RhoAN19 could competitively bind to a guanine nucleotide exchange factor common to Cdc42 and RhoA and thus indirectly inhibit activation of endogenous proteins.

Our morphological studies suggest that RhoA is the primary target of Galpha13, as expression of constitutively activated alpha13QL increased stress fiber formation, similar to a RhoAV14-induced phenotype. How acute activation of Galpha13 regulates the actin cytoskeleton is currently unknown, and we cannot exclude the possibility that transient activation of Galpha13 might also induce a Cdc42 phenotype. Concertina, a Drosophila homolog of Galpha13, also functions in cytoskeletal reorganization(58) . Concertina is critical for early gastrulation, as it coordinates cell shape changes during ventral furrow formation. Hence, regulation of the actin cytoskeleton may be a phylogenetically conserved function of Galpha13.

It is currently unknown whether the Rho-like GTPases divergently regulate NHE1 and the actin cytoskeleton or whether these effectors lie within a single signaling pathway. If the latter is true, then a critical question is whether activation of NHE1 occurs upstream or downstream of cytoskeletal reorganization. Cytoplasmic pH may be a potent modulator of cytoarchitecture, as the bundling and cross-linking of actin filaments are pH-dependent processes(54) . In Dictyostelium, changes in pH(i) over the physiological range seen in our study (6.9-7.2) produce dramatic reorganization of the actin cytoskeleton(54) . Additionally, pH(i)-influenced cytoskeletal remodeling has been suggested to modulate cell motility (55) , differentiation(56) , and protein synthesis(57) . NHE1 regulation could also occur downstream of cytoskeletal reorganization by the Rho-like GTPases, as osmotically induced changes in cell shape regulate Na-H exchange(2) .

At this point, it is not clear how MEK-, MEKK-, and Rho-mediated pathways couple to NHE1. Ultimately, these pathways must converge at the exchanger or at an upstream regulator of the exchanger. Using interaction cloning, we recently identified a novel protein, NIP1, that coprecipitates with NHE1 in vivo and regulates its activity. (^5)Overexpression of NIP1 interferes with Ras and Galpha13 activation of the exchanger, suggesting that the signaling pathways identified in this study may converge at NIP1 to regulate NHE1. The functional consequence of increased NHE1 activity remains unresolved. Constitutive activation of the GTPases and kinase cascades we studied induces neoplastic transformation, and transformed cells have a higher exchange activity and resting pH(i) than nontransformed cells(8, 9, 10) . The Rho and JNK pathways may also participate in cell volume regulation, and NHE1 is activated by osmotic challenge(2) . Whether activation of NHE1 plays either an obligatory or a permissive role in the cellular actions regulated by these three distinct signaling pathways remains to be determined.


FOOTNOTES

*
This work was supported by National Institutes of Health Grants GM 47413 and DK 40259 (to D. L. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Established Investigator for the American Heart Association. To whom correspondence should be addressed: HSW 604, Box 0512, University of California, San Francisco, CA 94143. Tel.: 415-476-3764; Fax: 415-476-4204; barber{at}itsa.ucsf.edu.

(^1)
The abbreviations used are: NHE1, ubiquitous Na-H exchanger; pH, intracellular pH; MAP, mitogen-activated protein; ERK, extracellular signal-regulated kinase; MEK, MAP kinase/ERK kinase; MEKK, MEK kinase; JNK, Jun kinase; D(2)R, D(2)-dopamine receptor.

(^2)
T. A. Voyno-Yasenetskaya and H. R. Bourne, personal communication.

(^3)
T. A. Voyno-Yasenetskaya and D. L. Barber, unpublished observations.

(^4)
C.-Y. Yu and D. L. Barber, unpublished observations.

(^5)
X. Lin and D. L. Barber, submitted for publication.


ACKNOWLEDGEMENTS

We thank Xia Lin and Chin-Yu Lin for valuable suggestions.

Note Added in Proof-Buhl et al. recently reported that alpha13QL stimulates a Rho-dependent increase in stress fiber formation (Buhl, A. M., Johnson, N. L., Dhanasekaran, N., and Johnson, G.(1995) J. Biol. Chem.270, 24631-24634).


REFERENCES

  1. Noel, J., and Pouyssegur, J. (1995) Am. J. Physiol. 268, C283-C296
  2. Grinstein, S., Woodside, M., Sardet, C., Pouyssegur, J., and Rotin, D. (1992) J. Biol. Chem. 267, 23823-23828 [Abstract/Free Full Text]
  3. Schwartz, M. A., Cragoe, E. J., Jr., and Lechene, C. P. (1990) J. Biol. Chem. 265, 1327-1332 [Abstract/Free Full Text]
  4. Vairo, G., Argyriou, S., Bordun, A. M., Gonda, T. J., Cragoe, E. J., Jr., and Hamilton, J. A. (1990) J. Biol. Chem. 265, 16929-16939 [Abstract/Free Full Text]
  5. Vairo, G., Cocks, B. G., Cragoe, E. J., Jr., and Hamilton, J. A. (1992) J. Biol. Chem. 267, 19043-19046 [Abstract/Free Full Text]
  6. Hazav, P., Shany, S., Moran, A., and Levy, R. (1989) Cancer Res. 49, 72-75 [Abstract]
  7. Rao, G. N., Sardet, C., Pouyssegur, J., and Berk, B. C. (1992) J. Cell. Physiol. 151, 361-366 [Medline] [Order article via Infotrieve]
  8. Hagag, N., Lacal, J. C., Graber, M., Aaronson, S., and Viola, M. V. (1987) Mol. Cell. Biol. 7, 1984-1988 [Medline] [Order article via Infotrieve]
  9. Maly, K., Uberall, F., Loferer, H., Doppler, W., Oberhuber, H., Groner, B., and Grunicke, H. H. (1989) J. Biol. Chem. 264, 11839-11842 [Abstract/Free Full Text]
  10. Kaplan, D. L., and Boron, W. F. (1994) J. Biol. Chem. 269, 4116-4124 [Abstract/Free Full Text]
  11. Sardet, C., Fafournoux, P., and Pouyssegur, J. (1991) J. Biol. Chem. 266, 19166-19171 [Abstract/Free Full Text]
  12. Wakabayashi, S., Bertrand, B., Shigekawa, M., Fafournoux, P., and Pouyssegur, J. (1994) J. Biol. Chem. 269, 5583-5588 [Abstract/Free Full Text]
  13. Voyno-Yasenetskaya, T., Conklin, B. R., Gilbert, R. L., Hooley, R., Bourne, H. R., and Barber, D. L. (1994) J. Biol. Chem. 269, 4721-4724 [Abstract/Free Full Text]
  14. Dhanasekaran, N., Prasad, M. V., Wadsworth, S. J., Dermott, J. M., and van Rossum, G. (1994) J. Biol. Chem. 269, 11802-11806 [Abstract/Free Full Text]
  15. Kitamura, K., Singer, W. D., Cano, A., and Miller, R. T. (1995) Am. J. Physiol. 268, C101-C110
  16. Stokoe, D., Macdonald, S. G., Cadwallader, K., Symons, M., and Hancock, J. F. (1994) Science 264, 1463-1467 [Medline] [Order article via Infotrieve]
  17. Leevers, S. J., Paterson, H. F., and Marshall, C. J. (1994) Nature 369, 411-414 [CrossRef][Medline] [Order article via Infotrieve]
  18. Kyriakis, J. M., Force, T. L., Rapp, U. R., Bonventre, J. V., and Avruch, J. (1993) J. Biol. Chem. 268, 16009-16019 [Abstract/Free Full Text]
  19. Seger, R., Ahn, N. G., Posada, J., Munar, E. S., Jensen, A. M., Cooper, J. A., Cobb, M. H., and Krebs, E. G. (1992) J. Biol. Chem. 267, 14373-14381 [Abstract/Free Full Text]
  20. Seger, R., and Krebs, E. G. (1995) FASEB J. 9, 726-735 [Abstract/Free Full Text]
  21. Gallego, C., Gupta, S. K., Heasley, L. E., Qian, N. X., and Johnson, G. L. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7355-7359 [Abstract]
  22. Voyno-Yasenetskaya, T. A., Pace, A. M., and Bourne, H. R. (1994) Oncogene 9, 2559-2565 [Medline] [Order article via Infotrieve]
  23. Faure, M., Voyno-Yasenetskaya, T. A., and Bourne, H. R. (1994) J. Biol. Chem. 269, 7851-7854 [Abstract/Free Full Text]
  24. Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420 [CrossRef][Medline] [Order article via Infotrieve]
  25. Inglese, J., Koch, W. J., Touhara, K., and Lefkowitz, R. J. (1995) Trends Biochem. Sci. 20, 151-156 [CrossRef][Medline] [Order article via Infotrieve]
  26. Xu, N., Voyno-Yasenetskaya, T., and Gutkind, J. S. (1994) Biochem. Biophys. Res. Commun. 201, 603-609 [CrossRef][Medline] [Order article via Infotrieve]
  27. Prasad, M. V., Shore, S. K., and Dhanasekaran, N. (1994) Oncogene 9, 2425-2429 [Medline] [Order article via Infotrieve]
  28. Prasad, M. V., Dermott, J. M., Heasley, L. E., Johnson, G. L., and Dhanasekaran, N. (1995) J. Biol. Chem. 270, 18655-18659 [Abstract/Free Full Text]
  29. Derijard, B., Raingeaud, J., Barrett, T., Wu, I. H., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) Science 267, 682-685 [Medline] [Order article via Infotrieve]
  30. Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Derijard, B., Davis, R. J., Johnson, G. L., and Karin, M. (1994) Science 266, 1719-1723 [Medline] [Order article via Infotrieve]
  31. Karin, M. (1995) J. Biol. Chem. 270, 16483-16486 [Free Full Text]
  32. Lange-Carter, C. A., and Johnson, G. L. (1994) Science 265, 1458-1461 [Medline] [Order article via Infotrieve]
  33. Engelberg, D., Klein, C., Martinetto, H., Struhl, K., and Karin, M. (1994) Cell 77, 381-390 [Medline] [Order article via Infotrieve]
  34. Bird, T. A., Kyriakis, J. M., Tyshler, L., Gayle, M., Milne, A., and Virca, G. D. (1994) J. Biol. Chem. 269, 31836-31844 [Abstract/Free Full Text]
  35. Lange-Carter, C. A., Pleiman, C. M., Gardner, A. M., Blumer, K. J., and Johnson, G. L. (1993) Science 260, 315-319 [Medline] [Order article via Infotrieve]
  36. Yan, M., Dai, T., Deak, J. C., Kyriakis, J. M., Zon, L. I., Woodgett, J. R., and Templeton, D. J. (1994) Nature 372, 798-800 [Medline] [Order article via Infotrieve]
  37. Lin, A., Minden, A., Martinetto, H., Claret, F. X., Lange-Carter, C., Mercurio, F., Johnson, G. L., and Karin, M. (1995) Science 268, 286-290 [Medline] [Order article via Infotrieve]
  38. Coso, O. A., Chiariello, M., Yu, J. C., Teramoto, H., Crespo, P., Xu, N., Miki, T., and Gutkind, J. S. (1995) Cell 81, 1137-1146 [Medline] [Order article via Infotrieve]
  39. Minden, A., Lin, A., Claret, F. X., Abo, A., and Karin, M. (1995) Cell 81, 1147-1157 [Medline] [Order article via Infotrieve]
  40. Ridley, A. J., and Hall, A. (1992) Cell 70, 389-399 [Medline] [Order article via Infotrieve]
  41. Nobes, C. D., and Hall, A. (1995) Cell 81, 53-62 [Medline] [Order article via Infotrieve]
  42. Kozma, R., Ahmed, S., Best, A., and Lim, L. (1995) Mol. Cell. Biol. 15, 1942-1952 [Abstract]
  43. MacNicol, A. M., Muslin, A. J., and Williams, L. T. (1993) Cell 73, 571-583 [Medline] [Order article via Infotrieve]
  44. Qiu, R. G., Chen, J., Kirn, D., McCormick, F., and Symons, M. (1995) Nature 374, 457-459 [CrossRef][Medline] [Order article via Infotrieve]
  45. Qiu, R. G., Chen, J., McCormick, F., and Symons, M. (1996) Proc. Natl. Acad. Sci. U. S. A. 92, 11781-11785 [Abstract]
  46. Barber, D. L., and Ganz, M. B. (1992) J. Biol. Chem. 267, 20607-20612 [Abstract/Free Full Text]
  47. Thomas, J. A., Buchsbaum, R. N., Zimniak, A., and Racker, E. (1979) Biochemistry 18, 2210-2218 [Medline] [Order article via Infotrieve]
  48. Boron, W. F., and De Weer, P. (1976) J. Gen. Physiol. 67, 91-112 [Abstract]
  49. Moodie, S. A., Willumsen, B. M., Weber, M. J., and Wolfman, A. (1993) Science 260, 1658-1661 [Medline] [Order article via Infotrieve]
  50. Olson, M. F., Ashworth, A., and Hall, A. (1995) Science 269, 1270-1272 [Medline] [Order article via Infotrieve]
  51. Deleted in proof
  52. Hill, C. S., Wynne, J., and Treisman, R. (1995) Cell 81, 1159-1170 [Medline] [Order article via Infotrieve]
  53. Hart, M. J., Eva, A., Zangrilli, D., Aaronson, S. A., Evans, T., Cerione, R. A., and Zheng, Y. (1994) J. Biol. Chem. 269, 62-65 [Abstract/Free Full Text]
  54. Edmonds, B. T., Murray, J., and Condeelis, J. (1995) J. Biol. Chem. 270, 15222-15230 [Abstract/Free Full Text]
  55. Van Duijn, B., and Inouye, K. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4951-4955 [Abstract]
  56. Gross, J. D., Bradbury, J., Kay, R. R., and Peacy, M. J. (1983) Nature 303, 244-245 [Medline] [Order article via Infotrieve]
  57. Aerts, R. J., Durston, A. J., and Moolenaar, W. H. (1985) Cell 43, 653-657 [Medline] [Order article via Infotrieve]
  58. Parks, S., and Wieschaus, E. (1991) Cell 64, 447-458 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.